Abstract P2-04-26: Identifying patient-specific neoepitopes for cell-based and vaccine immunotherapy across breast cancer classifications reveals rarely shared recurrent neoepitopes

Conclusion: TM with IBR after NACT is feasible surgical treatment option in breast cancer patients.canres;77/4_Supplement/P2-04-26/table1T1Clinicopathologic characteristicsVariablesControl group (n=85)Study group (n=31)p-valueAge, years (matching variables)0.890≤3515 (17.7)9 (29.0)36-5061 (71.8)21 (67.7)51≥9 (10.6)1 (3.2)BMI, m2/kg0.13025≤62 (72.9)28 (90.3)26-3018 (21.2)2 (6.5)30>5 (5.9)1 (3.2)Histology0.326Ductal carcinoma in situ2 (2.4)3 (9.7)Invasive ductal carcinoma74 (87.1)28 (90.3)Invasive lobular carcinoma2 (2.4)0 (0)Others7 (8.2)0 (0)Multiplicity0.063yes19 (22.6)12 (40.0)no65 (77.4)18 (60.0)Lymphovascular invasion0.161yes33 (39.3)17 (54.8)no51 (60.7)14 (45.2)Nuclear grade0.317Low10 (11.9)1 (3.3)Intermediate27 (32.1)14 (46.7)High47 (56.0)15 (24.2)Pathologic T stage (matching variable)0.154T17 (8.2)6 (19.4)T229 (34.1)15 (48.4)T331 (36.5)4 (12.9)T418 (21.2)6 (19.4)Pathologic N stage (matching variable)0.494N036 (42.4)13 (41.9)N123 (27.1)13 (41.9)N216 (18.8)4 (12.9)N310 (11.8)1 (3.2)Estrogen receptor0.608positive49 (57.7)15 (48.4)negative36 (42.4)16 (51.6)Progesterone receptor0.291positive40 (47.1)10 (32.3)negative45 (52.9)21 (67.7)HER2 status0.345amplification29 (34.1)10 (32.3)not amplification56 (65.9)21 (67.7)Clinical T-stage (matching variable)0.897cT12 (2.4)1 (3.2)cT231 (36.5)12 (38.7)cT346 (54.1)16 (51.6)cT46 (7.1)2 (6.5)Clinical N stage (matching variable)0.947cN03 (3.5)1 (3.2)cN120 (23.5)10 (32.3)cN236 (42.4)10 (32.3)cN326 (30.6)10 (32.3)Response (matching v...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Poster Session Abstracts Source Type: research